Key Takeaways
- A federal judge in Texas vacated most of a 2024 CMS rule designed to curb predatory Medicare Advantage marketing and rein in inflated broker payments.
- The decision, issued August 18, 2025, found that regulators overstepped their authority — leaning heavily on a landmark Supreme Court ruling that stripped federal agencies of broad interpretive power.
- Seniors may continue to be steered into plans that don’t suit their needs by brokers motivated by lucrative add-on payments that can exceed $1,300 per enrollee.
- One narrow provision survived: third-party marketers can no longer share a beneficiary’s personal information with other marketing organizations without consent.
Every fall, the Medicare open enrollment period arrives — and so does the deluge. Mailers pile up in seniors’ mailboxes. Phones ring with agents introducing themselves as representatives of “the Medicare program.” TV commercials broadcast glossy promises of free dental, free vision, and zero-dollar premiums. It’s a marketing blitz unlike anything else in American healthcare, and for years, lawmakers and patient advocates had been pushing to rein it in. Last year, it looked like they’d finally made headway. In April 2024, the medicare advantage marketing rule judge decision finalized a sweeping rule designed to align what brokers earn with what’s actually best for Medicare beneficiaries — not with whoever pays them the most. Then a federal judge in Texas paused the rule. And on August 18, 2025, Judge Reed O’Connor made that pause permanent, striking down the heart of the regulation and leaving seniors largely back where they started.
The Problem the Rule Was Trying to Solve
To understand why this ruling matters, it helps to understand what Medicare Advantage marketing actually looks like behind the scenes — because the picture is more complicated than a friendly insurance agent helping a grandparent pick a plan.
Medicare Advantage, or Part C, lets private insurers deliver medicare advantage marketing rule judge decision benefits. More than half of all Medicare beneficiaries are now enrolled in these plans, attracted by extra perks like dental and vision coverage that traditional Medicare doesn’t offer. Where there are tens of millions of potential customers, there is money — and where there is money, there are middlemen.
Spending by health insurers on agents’ and brokers’ fees and commissions nearly tripled between 2018 and 2023, rising from $2.4 billion to $6.9 billion. That’s taxpayer money, flowing through Medicare Advantage payments, eventually landing in the pockets of an ever-expanding ecosystem of brokers, field marketing organizations (FMOs), and lead generators.
Medicare sets a fixed commission cap for enrolling a new member. In 2024, that was $611 per new enrollee. With these add-on payments factored in, many brokers were collecting upwards of $1,300 per enrollee, according to the Alliance of Community Health Plans.
The natural result: brokers had every financial reason to push the plan that paid the most — not necessarily the one that covered a senior’s preferred doctors, or offered the benefits they actually needed. Beneficiary complaints of inappropriate Medicare Advantage marketing more than doubled from 2020 to 2021, according to a Senate Finance Committee investigation.
What CMS Did — and Why It Got Struck Down
In November 2023, CMS proposed a fix. By April 2024, it had finalized a rule that fixed broker and agent compensation, raised the pay cap for new enrollments, eliminated certain contracts between Medicare Advantage plans and third-party marketing organizations, and banned volume-based bonuses.
The intent was straightforward: if a broker earns the same amount no matter which plan they recommend, they’ll have less incentive to steer seniors toward the highest-paying option and more reason to actually find them the best fit. The rule also capped administrative payments — the workaround that had allowed total broker compensation to balloon so far beyond the official limit.
Industry groups sued almost immediately. Two organizations — Americans for Beneficiary Choice and the Council for Medicare Choice — filed separate lawsuits in Texas challenging the rule. Judge O’Connor consolidated the cases and, in July 2024, paused the rule while he considered the merits.
Then came the August 2025 ruling. O’Connor found that CMS overstepped its authority in trying to cap payments to Medicare Advantage sales organizations beyond direct compensation and in prohibiting contracts that incentivize brokers to steer seniors to specific plans.
The judge also invoked a major shift in administrative law. The decision leaned heavily on Loper Bright v. Raimondo, the Supreme Court’s June 2024 ruling that formally ended the Chevron doctrine — the principle that courts should defer to federal agencies’ interpretations of ambiguous statutes.
Beyond statutory authority, the court also found the vacated provisions “arbitrary and capricious” under the Administrative Procedure Act, ruling that the agency had provided insufficient justification for the $100 fixed fee amount, failed to adequately consider industry reliance interests, and had not sufficiently addressed public comments.
What Survived — and What Didn’t
Not everything fell. The court upheld one provision: a prohibition on third-party marketing firms distributing personal beneficiary data — names, addresses, phone numbers — to other marketing organizations without consent. That’s significant. The unrestricted sale of seniors’ contact information had created a situation where a single inquiry could result in dozens of calls from brokers who had purchased the same lead.
But the compensation caps, the prohibition on volume-based bonuses, and the restrictions on contracts that created financial incentives to steer beneficiaries toward specific plans? All gone.
Because O’Connor went beyond his preliminary injunction and ruled that CMS exceeded its statutory authority — rather than simply finding the rule poorly crafted — the decision makes it much harder for CMS to pass a similar rule in the future through ordinary rulemaking. The government had until October 17 to appeal. Given the change in administration and the current regulatory climate, legal analysts noted that an appeal appeared unlikely.
What This Means for Seniors Right Now
For the roughly 35 million Americans enrolled in medicare advantage marketing rule judge decision Advantage, the ruling doesn’t change their plans directly. But it reshapes the environment in which they’ll make future enrollment decisions — and that matters.
Beneficiaries are increasingly being steered toward plans that may not meet their needs because Medicare Advantage insurers are spending more to incentivize marketing and the generation of sales leads, thus raising the costs of the Medicare program overall.
As one Senate Finance Committee report put it: “By the time a beneficiary speaks with an insurance agent, they may have been steered based on minimal information about their health needs and are dramatically more likely to make an enrollment decision based on their conversation with a broker.”
For seniors navigating open enrollment, this makes the stakes of that conversation even higher. A broker who stands to earn significantly more for enrolling someone in Plan A than Plan B has a built-in reason — however unconscious — to emphasize Plan A’s strengths and minimize its drawbacks.
A Post-Chevron Healthcare Landscape
The ruling is also a signal about what’s coming in healthcare regulation more broadly. The Chevron doctrine had for decades given agencies like CMS wide latitude to fill in the gaps left by Congress — to interpret ambiguous statutes and craft detailed rules to implement them. Its elimination changes the math for regulators.
CMS and other federal agencies will now need to operate strictly within their statutory authority. Courts interpret the law themselves and are no longer inclined to defer to agency expertise when the statute isn’t crystal clear.
That creates a puzzle. Congress wrote the Medicare statute decades ago, long before the current Medicare Advantage marketing ecosystem existed. The law simply didn’t anticipate field marketing organizations, lead generators, or the complex chain of payments between insurers and third-party brokers. Regulatory attorneys expect CMS to propose new, narrower rules in upcoming rulemaking cycles — but the scope of what it can do without explicit Congressional authorization is now genuinely uncertain.
Advocates argue the decision underscores the need for Congress itself to act — to pass comprehensive Medicare marketing reform that would explicitly authorize the protections CMS tried to implement by regulation.
